T1	Participants 87 150	in AIDS patients in the Canadian randomized MAC treatment trial
T2	Participants 463 537	in HIV-positive patients with Mycobacterium avium complex (MAC) bacteremia
T3	Participants 674 734	Twenty-four hospital-based HIV clinics in 16 Canadian cities
